Amneal Pharmaceuticals Inc. (NYSE:AMRX) went up by 3.07% from its latest closing price compared to the recent 1-year high of $5.79. The company’s stock price has collected 11.26% of gains in the last five trading sessions. Press Release reported 17 hours ago that Amneal to Report Third Quarter 2020 Results on November 6, 2020
Is It Worth Investing in Amneal Pharmaceuticals Inc. (NYSE :AMRX) Right Now?
Plus, the 36-month beta value for AMRX is at 1.42. Opinions of the stock are interesting as 2 analysts out of 12 who provided ratings for Amneal Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 8 rated it as “hold,” and 2 as “sell.”
The average price from analysts is $4.50, which is -$0.69 below the current price. AMRX currently public float of 115.95M and currently shorts hold a 6.48% ratio of that float. Today, the average trading volume of AMRX was 1.13M shares.
AMRX’s Market Performance
AMRX stocks went up by 11.26% for the week, with a monthly jump of 19.15% and a quarterly performance of 3.70%, while its annual performance rate touched 73.79%. The volatility ratio for the week stands at 6.57% while the volatility levels for the past 30 days are set at 5.98% for Amneal Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 18.34% for AMRX stocks with a simple moving average of 19.29% for the last 200 days.
Analysts’ Opinion of AMRX
Many brokerage firms have already submitted their reports for AMRX stocks, with Goldman repeating the rating for AMRX by listing it as a “Sell.” The predicted price for AMRX in the upcoming period, according to Goldman is $4 based on the research report published on July 27th of the current year 2020.
AMRX Trading at 20.76% from the 50-Day Moving Average
After a stumble in the market that brought AMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.95% of loss for the given period.
Volatility was left at 5.98%, however, over the last 30 days, the volatility rate increased by 6.57%, as shares surge +17.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.36% lower at present.
During the last 5 trading sessions, AMRX rose by +11.26%, which changed the moving average for the period of 200-days by +4.56% in comparison to the 20-day moving average, which settled at $4.30. In addition, Amneal Pharmaceuticals Inc. saw 4.56% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at AMRX starting from Kiely John, who purchase 10,000 shares at the price of $4.40 back on May 19. After this action, Kiely John now owns 10,000 shares of Amneal Pharmaceuticals Inc., valued at $44,000 using the latest closing price.
George Jeffrey P., the Director of Amneal Pharmaceuticals Inc., purchase 23,810 shares at $4.16 during a trade that took place back on May 15, which means that George Jeffrey P. is holding 23,810 shares at $99,050 based on the most recent closing price.
Stock Fundamentals for AMRX
Current profitability levels for the company are sitting at:
- +0.09 for the present operating margin
- +29.46 for the gross margin
The net margin for Amneal Pharmaceuticals Inc. stands at -22.25. The total capital return value is set at 0.05, while invested capital returns managed to touch -11.79. Equity return is now at value -72.30, with -4.90 for asset returns.
Based on Amneal Pharmaceuticals Inc. (AMRX), the company’s capital structure generated 1,194.37 points at debt to equity in total, while total debt to capital is 92.27. Total debt to assets is 75.59, with long-term debt to equity ratio resting at 1,178.02. Finally, the long-term debt to capital ratio is 91.01.
Currently, EBITDA for the company is 76.55M with total debt to EBITDA at 12.94. When we switch over and look at the enterprise to sales, we see a ratio of 2.07, with the company’s debt to enterprise value settled at 0.82. The receivables turnover for the company is 2.79 and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.20.